Prospective study of 68Ga-NOTA-NFB: Radiation dosimetry in healthy volunteers and first application in glioma patients

Theranostics

Volumn 5, Issue 8, 2015, Pages 882-889

  Wang, Zhe ^a   Zhang, Mingru ^a   Wang, Liang ^b   Wang, Shengjun ^a   Kang, Fei ^a   Li, Guoquan ^a   Jacobson, Orit ^c   Niu, Gang ^c   Yang, Weidong ^a   Wang, Jing ^a   Chen, Xiaoyuan ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

^{68< sup>Ga NOTA NFB; CXCR4; Glioma; Internal dosimetry; PET CT}

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FLUORODEOXYGLUCOSE F 18; NOTA NFB GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN; GALLIUM;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; GENE OVEREXPRESSION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN EXPERIMENT; IMMUNOHISTOCHEMISTRY; LIVER; MALE; NEUROSURGERY; NORMAL HUMAN; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIATION DOSE; RADIOTHERAPY SOFTWARE; SENSITIVITY AND SPECIFICITY; SPLEEN; TREATMENT PLANNING; VOLUNTEER; AGED; MIDDLE AGED; PROCEDURES; RADIOMETRY;

ADULT; AGED; FEMALE; GALLIUM RADIOISOTOPES; GLIOMA; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOMETRY; RECEPTORS, CXCR4;

EID: 84941274831     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.12303     Document Type: Article

References (27)

1. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev. 2000; 177: 175-84.
2. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996; 382: 635-8.
3. Weiss ID, Jacobson O. Molecular imaging of chemokine receptor CXCR4. Theranostics. 2013; 3: 76-84.
4. Li M, RansohoffRM. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol. 2008; 84: 116-31.
5. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013; 49: 219-30.
6. Gagliardi F, Narayanan A, Reni M, Franzin A, Mazza E, Boari N, et al. The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions. Glia. 2014; 62: 1015-23.
7. Jacobson O, Weiss ID, Kiesewetter DO, Farber JM, Chen X. PET of tumor CXCR4 expression with 4-18F-T140. J Nucl Med. 2010; 51: 1796-804.
8. Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, et al. PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011; 52: 1803-10.
9. Aghanejad A, Jalilian AR, Fazaeli Y, Alirezapoor B, Pouladi M, Beiki D, et al. Synthesis and Evaluation of [67Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4. Sci Pharm. 2014; 82: 29-42.
10. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics. 2011; 1: 251-62.
11. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015; 5: 618-30.
12. Tamamura H, Omagari A, Hiramatsu K, Gotoh K, Kanamoto T, Xu Y, et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett. 2001; 11: 1897-902.
13. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. Improvement of CXCR4 tracer specificity for PET imaging. J Control Release. 2012; 157: 216-23.
14. Uemae Y, Ishikawa E, Osuka S, Matsuda M, Sakamoto N, Takano S, et al. CXCL12 secreted from glioma stem cells regulates their proliferation. J Neurooncol. 2014; 117: 43-51.
15. Liu C, Pham K, Luo D, Reynolds BA, Hothi P, Foltz G, et al. Expression and Functional Heterogeneity of Chemokine Receptors CXCR4 and CXCR7 in Primary Patient-Derived Glioblastoma Cells. PLoS One. 2013; 8: 1-12.
16. Wang S, Zhang S, Li J, Xu X, Weng Y, Zheng M, et al. CXCL12-induced upregulation of FOXM1 expression promotes human glioblastoma cell invasion. Biochem Biophys Res Commun. 2014; 447: 1-6.
17. Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, et al. 68Ga-PRGD2 PET/CT in the evaluation of glioma: A prospective study. Mol Pharm. 2014; 11: 3923-9.
18. la Fougere C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011; 13: 806-19.
19. Gagliardi F, Narayanan A, Reni M, Franzin A, Mazza E, Boari N, et al. The role of CXCR4 in highly malignant human gliomas biology: Current knowledge and future directions. Glia. 2014; 62: 1015-23.
20. Lv S, Sun B, Zhong X, Dai C, Wang W, Ma X, et al. The Clinical Implications of Chemokine Receptor CXCR4 in Grade and Prognosis of Glioma Patients: A Meta-Analysis. Mol Neurobiol. 2014 Sep 12. [Epub ahead of print] doi:10.1007/s12035-014-8894-3.
21. Hartimath SV, Waarde AV, Dierckx RAJO, Vries EFJd. Evaluation of N-[11C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model. Mol Pharm. 2014; 11: 3810-7.
22. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging αvß3 integrin levels. Radiology. 2011; 260: 182-91.
23. Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013; 54: 867-72.
24. Woodard LE, Nimmagadda S. CXCR4-based imaging agents. J Nucl Med. 2011; 52: 1665-9.
25. Demmer O, Gourni E, Schumacher U, Kessler H, Wester H-J. PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand. ChemMedChem. 2011; 6: 1789-91.
26. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015. doi:10.15252/emmm.201404698.
27. Herrmann K, Lapa C, Wester H-J, Schottelius M, Schiepers C, Eberlein U, et al. Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe 68Ga-Pentixafor. J Nucl Med. 2015; 56: 410-6.